HDL-C: does it matter? An update on novel HDL-directed pharmaco-therapeutic strategies

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Biochemistry

Background:

• Elevated low-density lipoprotein cholesterol (LDL-C) is a known cardiovascular disease (CHD) risk factor, though statins don't prevent all cases.
• Low high-density lipoprotein cholesterol (HDL-C) also correlates with increased CHD risk.
• Simply increasing HDL-C levels hasn't proven effective in clinical trials; HDL functionality is key.

Purpose of the Study:

• To review novel therapeutic strategies targeting high-density lipoprotein (HDL) for cardiovascular disease (CHD) risk reduction.
• To explore new drug development based on recent insights into HDL metabolism and function.
• To discuss approaches that enhance HDL functionality beyond simply increasing HDL-C concentration.

Main Methods:

• Review of recent scientific literature on HDL metabolism, function, and therapeutic targets.
• Classification of novel HDL-directed drugs based on their therapeutic approach.
• Discussion of strategies including apolipoprotein A-I (apo A-I) augmentation and enhancement of reverse cholesterol transport.

Main Results:

• Recent discoveries illuminate complex HDL metabolic and antiatherosclerotic pathways.
• New HDL-targeted drugs are being developed based on these insights.
• Therapeutic approaches focus on apo A-I concentration, HDL functionality, and reverse cholesterol transport.

Conclusions:

• Functional HDL, rather than just HDL-C levels, is a more promising therapeutic target for cardiovascular disease.
• Novel drug strategies aim to modulate HDL functionality through various mechanisms.
• Further research and clinical trials are needed to validate these new HDL-directed therapies.